- Home
- IDR vs ELDN Comparison
IDR vs ELDN Comparison
Compare IDR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- ELDN
- Stock Information
- Founded
- IDR 1996
- ELDN 2004
- Country
- IDR United States
- ELDN United States
- Employees
- IDR N/A
- ELDN N/A
- Industry
- IDR Precious Metals
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- ELDN Health Care
- Exchange
- IDR Nasdaq
- ELDN Nasdaq
- Market Cap
- IDR 154.1M
- ELDN 178.4M
- IPO Year
- IDR N/A
- ELDN N/A
- Fundamental
- Price
- IDR $12.80
- ELDN $2.79
- Analyst Decision
- IDR Strong Buy
- ELDN Strong Buy
- Analyst Count
- IDR 1
- ELDN 2
- Target Price
- IDR $17.50
- ELDN $12.50
- AVG Volume (30 Days)
- IDR 374.5K
- ELDN 618.2K
- Earning Date
- IDR 07-29-2025
- ELDN 08-18-2025
- Dividend Yield
- IDR N/A
- ELDN N/A
- EPS Growth
- IDR 144.40
- ELDN N/A
- EPS
- IDR 0.62
- ELDN N/A
- Revenue
- IDR $27,144,971.00
- ELDN N/A
- Revenue This Year
- IDR $9.76
- ELDN N/A
- Revenue Next Year
- IDR N/A
- ELDN N/A
- P/E Ratio
- IDR $20.62
- ELDN N/A
- Revenue Growth
- IDR 67.42
- ELDN N/A
- 52 Week Low
- IDR $9.55
- ELDN $2.30
- 52 Week High
- IDR $19.75
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- IDR 41.19
- ELDN 45.10
- Support Level
- IDR $12.40
- ELDN $2.60
- Resistance Level
- IDR $14.29
- ELDN $2.91
- Average True Range (ATR)
- IDR 0.59
- ELDN 0.17
- MACD
- IDR -0.09
- ELDN -0.00
- Stochastic Oscillator
- IDR 16.74
- ELDN 36.54
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.